Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020
Cited by 1,796 works. doi:10.1016/s0140-6736(20)32531-9
Authors
- Javier Cortés
- David W. Cescon
- Hope S. Rugo
- Zbigniew Ireneusz Nowecki
- Seock‐Ah Im
- Mastura Md Yusof
- Carlos Gallardo
- Oleg Lipatov
- Carlos H. Barrios
- Esther Holgado
- Hiroji Iwata
- Norikazu Masuda
- Marco Torregroza Otero
- Erhan Gökmen
- Sherene Loi
- Zifang Guo
- Gursel Aktan
- Vassiliki Karantza
- Peter Schmid
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- The blockade of immune checkpoints in cancer immunotherapy
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
- PD-1 and Its Ligands in Tolerance and Immunity
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- Pembrolizumab for Early Triple-Negative Breast Cancer
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- Multiple Testing in Group Sequential Trials Using Graphical Approaches